Complete Guide to Effectively Track Your Mounjaro (Tirzepatide) Treatment Daily: Injection Log, Weight Tracking, Side Effect Management, and Medical Reports.
Why Tracking is Essential with Mounjaro
Regular tracking of your tirzepatide (Mounjaro) treatment is a fundamental pillar of its success. According to a study published in Obesity Reviews (2023), patients who systematically document their treatment lose an average of 23% more weight compared to those who do not. This tracking helps identify trends, anticipate side effects, and optimize medical appointments.
Mounjaro acts on GLP-1 and GIP receptors, two incretin hormones involved in appetite regulation and glucose metabolism. Its weekly dosage with progressive titration (from 2.5 mg to 15 mg) requires careful monitoring to adjust doses at the right time. The World Obesity Federation (WOF) recommends multidimensional tracking including weight, measurements, diet, and psychological well-being.
The Injection Log: Your Number One Tool
Keeping an injection log is the first step to effective tracking. For each injection, note: the date and time, the administered dosage, the injection site (abdomen, thigh, arm), any incidents (leakage, pain, missed dose), and side effects experienced within the following 48 hours. This documentation allows your doctor to assess therapeutic adherence and adapt the dosing schedule.
The MounjaGO application offers a weekly reminder system with an integrated injection log. Each injection is recorded with the dosage, site, and observations. Data can be exported as a PDF for your medical consultations. This type of structured tracking is recommended by the French Society of Endocrinology (SFE) and the European Association for the Study of Obesity (EASO).
Weight Tracking: Frequency and Method
Weekly weighing is the standard recommended by endocrinologists. Weighing yourself daily can generate unnecessary stress because weight naturally fluctuates by 0.5 to 2 kg depending on hydration, hormonal cycle, and transit. Weigh yourself once a week, on the same day, at the same time (ideally in the morning on an empty stomach, after using the restroom), on the same scale. Record the weight in your tracking application.
Beyond weight, measure your body measurements monthly (waist circumference, hip circumference, chest circumference). The waist-to-hip ratio is a better indicator of metabolic health than weight alone. The SURMOUNT-1 study (NEJM 2022) showed that tirzepatide reduces waist circumference by an average of 14.5 cm at the 15 mg dose, which directly correlates with a reduction in cardiovascular risk.
Managing and Tracking Side Effects
Gastrointestinal side effects are the most frequent with Mounjaro: nausea (20-25%), diarrhea (12-17%), constipation (6-11%), vomiting (6-10%) according to SURMOUNT clinical trials. Documenting their frequency, intensity, and duration helps identify patterns and adapt treatment. For example, persistent nausea at a certain dose level may justify extending the titration period.
- Note each side effect with its start date and duration
- Assess intensity on a scale of 1 to 10
- Identify potential triggers (foods, injection time, activity)
- Immediately report to your doctor: severe abdominal pain, visual disturbances, significant skin reactions
- Use the MounjaGO application’s graphs to visualize trends
Medical PDF Reports
A structured medical report is a valuable asset for your consultations. The MounjaGO application automatically generates a PDF report containing: the complete injection history with dates and dosages, the weight curve with trend, a summary of side effects, body measurements, and personal notes. This document allows your doctor to make informed decisions at a glance.
The French National Authority for Health (HAS) encourages the use of digital patient tracking tools for chronic diseases. A well-structured report facilitates doctor-patient communication and optimizes consultation time. Export your report 24 to 48 hours before your appointment so your doctor can review it in advance if you share it via secure email.
Nutritional and Physical Activity Tracking
Tirzepatide treatment profoundly changes appetite and eating behaviors. Nutritional tracking ensures that protein intake (minimum 1.2 g/kg/day), vitamins, and minerals remain adequate despite reduced appetite. Sarcopenia (loss of muscle mass) is a real risk during rapid weight loss, and sufficient protein intake combined with physical exercise prevents it.
Physical activity is an essential complement to treatment. The WHO recommends 150 minutes of moderate activity per week. Record your exercise sessions with type, duration, and intensity. The combination of exercise + tirzepatide preserves muscle mass and optimizes body composition. Data from the SURMOUNT-4 study confirm that regular physical activity improves weight loss maintenance after dose stabilization.
Track your progress with the MounjaGO application.
FAQ
How often should I weigh myself while on Mounjaro?
Weekly weighing is recommended by endocrinologists. Weigh yourself once a week, on the same day, at the same time (morning on an empty stomach), on the same scale. Daily fluctuations of 0.5 to 2 kg are normal and do not reflect the actual trend.
What side effects should I note in my log?
Note all side effects: nausea, diarrhea, constipation, fatigue, headaches, injection site reactions. Indicate the date, duration, intensity (1-10), and any potential triggers. Consult your doctor immediately in case of severe abdominal pain or visual disturbances.
How long does it take to see the first results?
The first results generally appear between 4 and 8 weeks after the start of treatment, during the titration phase at 2.5 mg then 5 mg. Significant weight loss accelerates at therapeutic doses of 10 mg and 15 mg according to SURMOUNT trials.
How do I share my tracking with my doctor?
The MounjaGO application generates an exportable PDF report containing your injection history, weight curve, side effects, and body measurements. Export it 24 to 48 hours before your appointment and share it via secure email or print it.